FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039457499> ?p ?o ?g. }

• W3039457499 endingPage "1808" @default.
• W3039457499 startingPage "1797" @default.
• W3039457499 abstract "Abstract Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma with a proclivity for systemic dissemination, leading many patients to present with advanced stage disease and fail available treatments. There is a notable lack of targeted therapies for NPC, despite working knowledge of multiple proteins with integral roles in NPC cancer biology. These proteins include EZH2, Snail, eIF4E, and IMPDH, which are all overexpressed in NPC and correlated with poor prognosis. These proteins are known to be modulated by ribavirin, an FDA-approved hepatitis C antiviral that has recently been repurposed as a promising therapeutic in several solid and hematologic malignancies. Here, we investigated the potential of ribavirin as a targeted anticancer agent in five human NPC cell lines. Using cellular growth assays, flow cytometry, BrdU cell proliferation assays, scratch wound assays, and invasion assays, we show in vitro that ribavirin decreases NPC cellular proliferation, migration, and invasion and promotes cell-cycle arrest and cell death. Modulation of EZH2, Snail, eIF4E, IMPDH, mTOR, and cyclin D1 were observed in Western blots and enzymatic activity assays in response to ribavirin treatment. As monotherapy, ribavirin reduced flank tumor growth in multiple NPC xenograft models in vivo. Most importantly, we demonstrate that ribavirin enhanced the effects of radiotherapy, a central component of NPC treatment, both in vitro and in vivo. Our work suggests that NPC responds to ribavirin-mediated EZH2, Snail, eIF4E, IMPDH, and mTOR changes and positions ribavirin for clinical evaluation as a potential addition to our NPC treatment armamentarium." @default.
• W3039457499 created "2020-07-10" @default.
• W3039457499 creator A5006008176 @default.
• W3039457499 creator A5010219978 @default.
• W3039457499 creator A5017358523 @default.
• W3039457499 creator A5021949677 @default.
• W3039457499 creator A5023833032 @default.
• W3039457499 creator A5027322124 @default.
• W3039457499 creator A5039709663 @default.
• W3039457499 creator A5045785216 @default.
• W3039457499 creator A5049209796 @default.
• W3039457499 creator A5049334243 @default.
• W3039457499 creator A5050597052 @default.
• W3039457499 creator A5055192528 @default.
• W3039457499 creator A5060287350 @default.
• W3039457499 creator A5063653642 @default.
• W3039457499 creator A5064732668 @default.
• W3039457499 creator A5064814225 @default.
• W3039457499 creator A5066615498 @default.
• W3039457499 creator A5071922535 @default.
• W3039457499 creator A5072527942 @default.
• W3039457499 creator A5082351363 @default.
• W3039457499 creator A5086406025 @default.
• W3039457499 date "2020-09-01" @default.
• W3039457499 modified "2023-09-23" @default.
• W3039457499 title "Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma" @default.
• W3039457499 cites W1964230671 @default.
• W3039457499 cites W1968622004 @default.
• W3039457499 cites W1968700203 @default.
• W3039457499 cites W1976585056 @default.
• W3039457499 cites W1977090021 @default.
• W3039457499 cites W1985735252 @default.
• W3039457499 cites W1989591919 @default.
• W3039457499 cites W1999769013 @default.
• W3039457499 cites W2031631676 @default.
• W3039457499 cites W2033120379 @default.
• W3039457499 cites W2033489247 @default.
• W3039457499 cites W2079066605 @default.
• W3039457499 cites W2082834726 @default.
• W3039457499 cites W2084615115 @default.
• W3039457499 cites W2088174971 @default.
• W3039457499 cites W2089821881 @default.
• W3039457499 cites W2109428486 @default.
• W3039457499 cites W2112519486 @default.
• W3039457499 cites W2112606352 @default.
• W3039457499 cites W2115591535 @default.
• W3039457499 cites W2131071584 @default.
• W3039457499 cites W2143104089 @default.
• W3039457499 cites W2149546612 @default.
• W3039457499 cites W2150434794 @default.
• W3039457499 cites W2169508419 @default.
• W3039457499 cites W2170704231 @default.
• W3039457499 cites W2188257337 @default.
• W3039457499 cites W2264682687 @default.
• W3039457499 cites W2461456620 @default.
• W3039457499 cites W2510616818 @default.
• W3039457499 cites W2512237822 @default.
• W3039457499 cites W2560194197 @default.
• W3039457499 cites W2562383504 @default.
• W3039457499 cites W2605119272 @default.
• W3039457499 cites W2757843953 @default.
• W3039457499 cites W2781832221 @default.
• W3039457499 cites W2890861459 @default.
• W3039457499 cites W2902454944 @default.
• W3039457499 cites W2914744786 @default.
• W3039457499 cites W2936768572 @default.
• W3039457499 cites W2953842076 @default.
• W3039457499 cites W4210983491 @default.
• W3039457499 cites W4211156657 @default.
• W3039457499 cites W986753386 @default.
• W3039457499 doi "https://doi.org/10.1158/1535-7163.mct-19-0572" @default.
• W3039457499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32606016" @default.
• W3039457499 hasPublicationYear "2020" @default.
• W3039457499 type Work @default.
• W3039457499 sameAs 3039457499 @default.
• W3039457499 citedByCount "7" @default.
• W3039457499 countsByYear W30394574992021 @default.
• W3039457499 countsByYear W30394574992022 @default.
• W3039457499 countsByYear W30394574992023 @default.
• W3039457499 crossrefType "journal-article" @default.
• W3039457499 hasAuthorship W3039457499A5006008176 @default.
• W3039457499 hasAuthorship W3039457499A5010219978 @default.
• W3039457499 hasAuthorship W3039457499A5017358523 @default.
• W3039457499 hasAuthorship W3039457499A5021949677 @default.
• W3039457499 hasAuthorship W3039457499A5023833032 @default.
• W3039457499 hasAuthorship W3039457499A5027322124 @default.
• W3039457499 hasAuthorship W3039457499A5039709663 @default.
• W3039457499 hasAuthorship W3039457499A5045785216 @default.
• W3039457499 hasAuthorship W3039457499A5049209796 @default.
• W3039457499 hasAuthorship W3039457499A5049334243 @default.
• W3039457499 hasAuthorship W3039457499A5050597052 @default.
• W3039457499 hasAuthorship W3039457499A5055192528 @default.
• W3039457499 hasAuthorship W3039457499A5060287350 @default.
• W3039457499 hasAuthorship W3039457499A5063653642 @default.
• W3039457499 hasAuthorship W3039457499A5064732668 @default.
• W3039457499 hasAuthorship W3039457499A5064814225 @default.
• W3039457499 hasAuthorship W3039457499A5066615498 @default.
• W3039457499 hasAuthorship W3039457499A5071922535 @default.

• next